Conditions: Abscess Wound Infection Surgical Site Infection Cellulitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 573
Healthy volunteers: no

Brief summary:
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Dalbavancin intervention 2: Vancomycin / Linezolid
Intervention descriptions: intervention 1: IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8 intervention 2: IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.

Protocol document: